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Introduction
This supplement to Kidney International contains some
of the proceedings of the Fourth International Confer-
ence on Hypertension and the Kidney. The Conference,
held in Madrid in February 2004, was organized by the
Department of Nephrology of the Hospital General, Uni-
versitario Gregorio Maran˜o´n, under the sponsorship of
the Universidad Complutense de Madrid, Spanish So-
ciety of Nephrology, Spanish Society of Hypertension,
European Renal Association–European Dialysis and
Transplant Association, and European Society of
Hypertension.
During the past years, increasing evidence has shown
that chronic kidney disease (CKD), whether manifest
by elevated serum creatinine, albuminuria, or reduced
glomerular filtration rate, is associated with a high risk
of cardiovascular disease (CVD), independently of its
origin. A statement from the councils on Kidney in
Cardiovascular Disease, High Blood Pressure Research,
Clinical Cardiology and Epidemiology, and Prevention of
the American Heart Association [1] has recently summa-
rized the evidence for kidney disease as a risk factor for
the development of CVD and recommended that patients
with chronic kidney disease be considered as members
of the “highest risk group” for subsequent cardiovascu-
lar disease events. Several prospective studies reported
the strong association between chronic kidney disease
and cardiovascular disease. Data from over 15,000 adults
aged 45 to 65 years at baseline followed for five years in
the Atherosclerosis Risk in Communities study showed
that reduced kidney function is an independent risk factor
for both de novo and recurrent CVD [2]. In the Cardio-
vascular Health Study, an elevated serum creatinine level
was associated with an approximately twofold higher risk
of overall and CVD mortality. After adjustment for car-
diovascular risk factors and subclinical disease measures,
elevated serum creatinine remained an independent risk
factor for these outcomes, as well as those for total CVD,
congestive heart failure (CHF), and claudication. In the
Coronary Prevention Project, one-year mortality after a
myocardial infarction increased from 24% to 46% and
66% among patients with a serum creatinine less than
1.5 mg/dL, 1.5 to 2.4 mg/dL, and 2.5 to 3.9 mg/dL, respec-
tively. After adjustment for patient and treatment char-
acteristics, elevated serum creatinine was independently
associated with a substantially elevated risk of death dur-
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ing the first month after a myocardial infarction. The pre-
dictive capacity of small increases in serum creatinine
has been confirmed by the data of the Intervention as a
Goal in Hypertension Treatment study (INSIGHT), Sys-
tolic Hypertension in Europe study (SYST-EUR), Sys-
tolic Hypertension in China (SYST-China), and Systolic
Hypertension in the Elderly Program (SHEP) study. In
fact, the predictive power of serum creatinine was com-
parable to that of other well-established risk factors, such
as diabetes or a history of myocardial infarction, in the
HOT study [3]. A negative correlation between risk of
CVD and glomerular filtration rates was reported both
in middle-aged and elderly cohorts even after adjust-
ment for a large number of risk factors. Even mildly
reduced kidney function (60–89 mL/min/1.73m2) was as-
sociated with an increased risk of CVD. On the other
hand, albuminuria, even at low levels, predicted cardio-
vascular risk among 40,548 adults from Groningen in The
Netherlands [4]. Similar findings were reported in the
Heart Outcomes Prevention Evaluation study (HOPE)
[5]. In this study, renal insufficiency was an independent
predictor of cardiovascular events. Twenty-two percent
of patients with mild renal insufficiency experienced car-
diovascular death, myocardial infarction (MI), or stroke
over the four-year follow-up period compared with 15%
of patients without renal insufficiency, an increased rela-
tive risk of 46%. The increased risk was proportional to
serum creatinine.
Cardiovascular risk in post-transplant patients shares
many similarities with cardiovascular risk in the general
population, as well as in those with mild-to-moderate re-
nal dysfunction. Compared with the general population,
cardiovascular mortality in transplant patients, stratified
by age, is increased almost 10-fold between the ages of 35
and 44 years, and is at least doubled between the ages of
55 and 64 years. Although renal transplantation reduces
the risk of cardiovascular events compared to mainte-
nance dialysis, the transplant population remains at high
risk of cardiovascular morbidity and mortality. In addi-
tion to the cardiovascular risk factors shared with the
general population, pretransplant cardiovascular risk fac-
tors, post-transplant renal function, and immunosuppres-
sive therapy are predictive of cardiovascular risk in renal
transplant recipients [6].
The presence of CKD is not only accompanied by
more primary CV events and death. Conversely, tradi-
tional cardiovascular risk factors, such as hypertension,
metabolic syndrome, and dyslipidemia also increase the
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risk of CKD. In addition, a number of nontraditional
cardiovascular risk factors that are markers of inflam-
mation and endothelial dysfunction are also predic-
tive of CKD. Detection of a slightly decreased value
of creatinine clearance is accompanied by higher lev-
els of blood pressure, higher uric acid and triglyc-
eride levels, and lower levels of high-density lipoprotein
cholesterol. A similar clustering of risk factors has been
reported in microalbuminuric subjects, in particular,
those linked to insulin resistance. Available data in hy-
pertensive patients point to the association between CKD
and the components of the metabolic syndrome. Recent
data have shown that among young hypertensive patients
with metabolic syndrome, the presence of minor abnor-
malities of renal function is mostly related to the presence
of insulin resistance, together with high blood pressure
[7].
Simultaneous correction or prevention of renal and
cardiovascular damage is required in these patients.
Lifestyle changes, with particular emphasis on dimin-
ishing salt intake, avoiding obesity, and refraining from
smoking are very important. Treatment of dyslipidemia
with statins confers similar benefit to CKD patients as
to nonrenal patients. A number of clinical trials have
been initiated to test therapies for CVD risk reduc-
tion in CKD. These have focused on dyslipidemia, hy-
perhomocysteinemia, hypertension, and anemia. Strict
blood pressure control (preferably below 125/75 mm Hg)
is required. Combinations of drugs are needed in
most cases. Angiotensin-converting enzyme inhibitors
and angiotensin receptor blockers have been shown
to improve the long-term renal outcome of patients
with nephrosclerosis. Furthermore, dual blockade of
the renin-angiotensin system with both an angiotensin-
converting enzyme inhibitor and an angiotensin II
receptor blocker has been shown to safely retard the pro-
gression of nondiabetic renal disease compared with ei-
ther drug alone [8].
In summary, in the general population, individuals with
CKD are at a high risk for cardiovascular events. How-
ever, the precise mechanisms connecting renal function
and cardiovascular risk remain to be established. Another
question that arises is the direction of causality between
cardiovascular disease and renal dysfunction. Numerous
studies have suggested that treatment with antihyperten-
sive agents can slow the progression of renal disease. In
several of these studies, the observed renoprotective ef-
fects were greater than what was expected for blood pres-
sure lowering alone, suggesting a more complex action.
These findings, together with the observation of a reduced
risk of cardiovascular death after transplantation, sug-
gest that the relationship between renal insufficiency and
cardiovascular disease may, in fact, be bidirectional. The
Fourth International Conference on Hypertension and
the Kidney updated different aspects of this relationship.
Some of those lectures are presented in this supplement.
We are grateful to all of the distinguished contributors
to this Conference for both their lectures at the event and
their articles that comprise this supplement. We would
like to thank all the sponsors and pharmaceutical com-
panies, their generous contribution that supported the
Meeting, and the publication of this issue. Finally, we ex-
press our deepest gratitude for the interest and leadership
shown by the Editor of Kidney International, Dr. Saulo
Klahr, who kindly favored the publication of this special
issue.
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